Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Macerich Company (The) Common Stock (MAC) Price & Performance

Inovio Pharmaceuticals IncTrade
Macerich Company (The) Common StockTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Macerich Company (The) Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.98 (market cap $101.95M), while Macerich Company (The) Common Stock trades at $22.18 (market cap $6.29B). The key difference: Macerich Company (The) Common Stock is far larger — about 61.7× Inovio Pharmaceuticals Inc's market cap, and Macerich Company (The) Common Stock pays a 3.07% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Macerich Company (The) Common Stock for 0 Days on average.

INOMAC
Market Cap
$101.95M$6.29B
Volume
2,985,8473,158,142
Sector
HealthReal Estate
52-Week High
$2.60$26.51
52-Week Low
$0.66$16.20
Typical Hold Time
43 Days0 Days
Enterprise Value
$73.28M$10.97B
Dividend Yield
—3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal and negative financial metrics including a net income margin of -130,000%. The company shows consistent quarterly earnings beats but faces significant cash burn, with operating cash flow negative at -$88.63M in 2025. Key near-term catalyst is the FDA decision on INO-3107 expected by October 30, 2026.

INO presents high-risk speculative opportunity with analyst consensus price target of $2.75 representing 175% upside potential. The investment case hinges on successful FDA approval and commercialization of INO-3107, but carries substantial risk from persistent losses, negative cash flow, and dependence on financing activities to sustain operations.

Macerich Company (The) Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
97% Buy3% Sell
Avg holding period · 43 Days
MAC
100% Buy0% Sell
Avg holding period · 0 Days

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About Macerich Company (The) Common Stock

The Macerich Company is a real estate investment trust that owns, operates, and redevelops shopping centers concentrated in California, the Pacific Northwest, and other major US markets.

Read more on MAC →